Language selection

Search

Patent 3139871 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 3139871
(54) English Title: PURIFIED FISH PROTEASES WITH HIGH SPECIFIC ACTIVITIES AND ITS PROCESS OF PRODUCTION
(54) French Title: PROTEASES DE POISSON PURIFIEES AYANT DES ACTIVITES SPECIFIQUES ELEVEES ET LEUR PROCEDE DE PRODUCTION
Status: Examination
Bibliographic Data
(51) International Patent Classification (IPC):
  • C12N 09/64 (2006.01)
  • C07K 01/14 (2006.01)
  • C07K 01/20 (2006.01)
  • C07K 01/36 (2006.01)
(72) Inventors :
  • YOUSIF, ALEX NOBAR (Canada)
  • DUTTA PASSECKER, PRIYANKA (Austria)
  • FERRARI, VALERIO MARIA (Italy)
  • SIDDHARTH, JAY (Switzerland)
(73) Owners :
  • BIOSEUTICA B.V.
(71) Applicants :
  • BIOSEUTICA B.V.
(74) Agent: KIRBY EADES GALE BAKER
(74) Associate agent:
(45) Issued:
(86) PCT Filing Date: 2020-04-27
(87) Open to Public Inspection: 2020-11-19
Examination requested: 2024-04-22
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/EP2020/061588
(87) International Publication Number: EP2020061588
(85) National Entry: 2021-11-10

(30) Application Priority Data:
Application No. Country/Territory Date
62/847,013 (United States of America) 2019-05-13

Abstracts

English Abstract

The invention concerns a process for the preparation of fish proteases from fish viscera, preferably from cod (Gadus genus) viscera. The fish proteases produced according to the invention have high specific enzymatic activity and are useful for food uses, for biomedical applications, in histology and tissue culture.


French Abstract

L'invention concerne un procédé de préparation de protéases de poisson à partir de viscères de poisson, de préférence à partir de viscères de cabillaud (genre Gadus). Les protéases de poisson produites selon l'invention présentent une activité enzymatique spécifique élevée et sont utiles pour des utilisations alimentaires, pour des applications biomédicales, en histologie et en culture tissulaire.

Claims

Note: Claims are shown in the official language in which they were submitted.


CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
16
CLAIMS
1. A process of purification of fish proteases from fish viscera, said
proteases having
an average specific enzymatic activity of Trypsin of 240 U/mg 40 U/mg,
Chymotrypsin
activity of 4 2 U/mg, Collagenase activity of 0,04 0,02 U/mg and a Protease
activity of
65 10 U/mg comprising:
a) Extraction of crude enzyme from fish viscera with a calcium chloride buffer
at pH
7, filtration and ultrafiltration;
b) Extraction of the ultrafiltrate with an aqueous solution of CaC12 having
conductivity from 52 to 62 mS in a pH range of 7,8 8,2 followed by depth
filtration;
c) Purification by hydrophobic interaction chromatography of the filtrate
using as
stationary phases an agarose base matrix with straight chain alkyl ligands or
aryl
ligands and eluted by elution with buffers of low salt content and then with
an
aqueous mixture of water miscible organic solvents and a polyol;
d) Dialysis;
e) Optional freeze-drying.
2. A process according to claim 1 wherein the fish viscera are cod
viscera.
3. A process according to the claim 1 wherein step a) is carried out at
a temperature
between 4 and 25 C.
4. A process according to claim 1 wherein the calcium ions of step a) are
derived from
calcium chloride at a final concentration of 20 mM.
5. A process according to claim 1 wherein the ultrafiltration of step a) is
carried out
using a membrane with a 1 kDalton cut off
6. A process according to claim 1 wherein the agarose base matrix of the
stationary
phase used in step c) presents aryl ligands and a particle size distribution
between 50 and
100 microns.
7. A process according to claim 1 wherein the chromatographic elution with
buffers
of low salt content in step b) is done using a 1,5 M aqueous sodium acetate
solution.

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
17
8. A process according to claim 1 wherein the water miscible organic
solvent utilized
in the chromatographic elution in step c) is isopropanol.
9. A process according to claim 1 wherein the polyol utilized as component
of the
chromatographic elution in step c) is glycerol.
10. A process according to the claim 1 wherein step c) is carried out at a
temperature
between 4 and 25 C.
11. A process according to claim 1 wherein step e) is not carried out
and the fish
proteases are isolated in an aqueous solution directly from the step d) at the
desired final
concentration.
12. Fish proteases with an average specific of Trypsin activity of 240 40
U/mg,
Chymotrypsin activity of 4 2 U/mg, Collagenase activity of 0,04 0,02 U/mg
and a
Protease activity of 65 10 U/mg obtained by the process of claims 1-11.
13. Formulations comprising the fish proteases of claim 12, 0,1-0,3 g/L of
potassium
chloride and potassium dihydrogen phosphate, 7-9 g/L of NaC1, 1,0-1,3 g/L of
disodium
monohydrogen phosphate, 2.4 mg/L of phenol red and sodium
ethylenediaminetetraacetate
at a final concentration ranging between 0,3 and 0,6 mM.
14. The use of fish proteases of claim 12 for food, biomedical
applications, in histology
and tissue culture.
15. The use of fish proteases of claim 12 in in histology and tissue
cultures of PC12 and
NPC cell lines.

Description

Note: Descriptions are shown in the official language in which they were submitted.


CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
PURIFIED FISH PROTEASES WITH HIGH SPECIFIC ACTIVITIES AND ITS
PROCESS OF PRODUCTION
Field of the Invention
The invention concerns a process for the preparation of fish proteases from
fish
viscera, preferably from cod (Gadus genus) viscera. The fish proteases
produced according
to the invention have high specific enzymatic activity and are useful for food
uses, for
biomedical applications, in histology and tissue culture.
Background
The proteolytic activity of trypsin (EC 3.4.21.4) was first described in 1876
by
W. Kuhne in pancreatic secretions ("Uber das Trypsin (Enzym des Pankreas)",
Verhandlungen des naturhistorisch-medicinischen Vereins zu Heidelberg, vol. 1,
no. 3,
pages 194-198).
This enzyme specifically hydrolyzes peptide bonds C-terminal to the amino acid
residues of lysine and arginine about one hundred times faster than a basic
hydrolysis. Since
its initial discovery, trypsin has been identified in all animals, including
insects, fish, and
mammals. Trypsin from each source differs slightly in activity, but the
natural substrate for
the enzyme is any peptide that contains lysine or arginine.
Human trypsin hydrolyzes peptide bonds after arginine or lysine residues, its
activity being optimal between pH 7.5 and 8.5 and in the presence of calcium
ions;
moreover, human trypsin has optimal operating temperature of about 37 C.
Fish trypsins, such as those isolated from Atlantic cod, have different
optimal
temperature ranges (as poikilotherm organisms like fish live at low body
temperatures). For
example, cod trypsins include trypsin I, having a maximal temperature activity
range of 4
to 65 C and maximal activity at 55 C, and trypsin Y having an activity range
comprised
between 2 and 30 C and a maximal activity at 21 C (Gudmundsdottir A et al.,
2005
Mar-Apr;7(2):77-88); Hindawi Publishing Corporation; BioMed Research
International,
Volume 2013, Article ID 749078). Another relevant difference between mammalian
and

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
2
fish trypsins is their thermal stability: for example, fish trypsins but not
mammalian trypsins
are completely inactivated by a pasteurization process. As a protein, trypsin
shows various
molecular weights depending on the source. For example, a molecular weight of
23.3 kDa
is reported for trypsin from bovine and porcine sources, while fish trypsin I,
trypsin X and
trypsin Y, isolated from Atlantic cod, have molecular masses of 23.9 kDa, 23.9
kDa and
25.1 kDa, respectively (Bjarki Stefansson et al., Characterization of cold-
adapted Atlantic
cod (Gadus morhua) trypsin I ¨ Kinetic parameters, autolysis and thermal
stability;
Comparative Biochemistry and Physiology, Part B; (2010) 186-194).The
commercial
applications of trypsins may include, inter al/a, their use in the development
of cell and
tissue culture protocols (Soleimani M.; Nadri S. A, Nature protocols (2009),
4(1), 102-6),
in the protein identification through peptide sequencing techniques (Schuchert-
Shi et al.,
Analytical Biochemistry (2009), 387(2), 202-207) and in the medical field to
model the
decomposition of articular cartilage in osteoarthritis (Wang S. et al.,
Connective tissue
research (2010), 51(1), 36-47). Particularly fish trypsin (Atlantic cod
trypsin I) has already
proved its usefulness in a variety of industrial applications (Bjarnason, J.B.
et al.,
Psychrophilic proteinases from Atlantic cod ACS Symposium Series (1993), 516
(Biocatalyst Design for Stability and Specificity), 68-82) including the
production of an
all-natural seafood flavour from lobster, shrimp, crab, and other seafood.
More recently,
cod trypsin has shown high efficacy in degradation of native proteins and in
vitro
anti-pathogenic efficacy against HSV-1 and RSV, opening new perspectives for
new
therapeutic uses of fish proteases (BioMed Research International Volume 2013,
Article
ID 749078, http://dx.doi.org/10.1155/2013/749078). A critical aspect of the
use of
proteases, and also of marine trypsins, is their stability, as they undergo
autolysis. For this
reason, they should be stored at very low temperatures (between -20 and -80 C)
to prevent
.. degradation. Autolysis may be controlled by keeping these proteases at pH 3
or by using
proteases modified by reductive methylation. Serine proteases (a class of
proteases which
also include trypsin) show restored activity when the pH is adjusted back to
pH 8,
(F.M. Pohl European J. Biochem. 7 (1968), 146-152; Aizawa, N.; Yokohama
Medical

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
3
Bulletin (1960), 11, 101-10) although an important loss of activity when
working under
very alkaline conditions (pH 10) is described (B. K. Khangembam et al.,
International
Aquatic Research, December 2012, 4:9).Commercially available marine proteases
extracted from the gut of crustaceans, and identified by the CAS registry
number
534583-22-7 (trade name Accutase), are also temperature sensitive: they are
stable at 4 C
for 60 days but quickly lose 75% of their enzymatic activity (in 90 minutes)
when stored at
37 C.
The standardization of the characteristics of these purified trypsins and
proteases,
in terms of stability and enzymatic activities, is important in view of their
commercial use,
as they could be validated for use as production reagents (e.g. in the food
chemistry) and in
histology and tissue culture. The pyloric cecum of Atlantic cod, acting as a
digestive organ,
is a by-product of the fishing industry and can be utilized as a cheap
starting material for
the isolation of fish proteases, including trypsins. It is rich in digestive
enzymes such as
serine proteases (Asgeirsson B. et al., Eur J Biochem 180(1), 85-94).
The best known members of these serine protease family from Atlantic cod are
trypsins, chymotrypsins, elastases, serine collagenases, and brachyurins
(Halfon S, Craik
CS (1998) "Family 51 of trypsin (clan SA)" In: Handbook of Proteolytic
Enzymes, Barrett
AJ, Rawlings ND, Woessner JF, eds. (San Diego, Calif: Academic Press) pp 5-
12). In
more detail, three native trypsin isozymes, termed trypsins I, II, and III,
were isolated from
the pyloric ceca of Atlantic cod. Trypsin I, the most abundant and best
characterized form,
also shows the highest catalytic efficiency which is approximately 20 times
higher than that
of its mesophilic bovine analogue. The known methods of purification of
proteases from
fish viscera (Comparative biochemistry and physiology. Part B, Biochemistry &
molecular
biology (1995), 110(4), 707-17; Journal of Agricultural and Food Chemistry, 39
(10), Pages
1738-42 (1991)) are however quite complex and require several purification
steps which
may
include, inter alia, (NH4)250 4 fractionation and several chromatographic
purifications, including hydrophobic interaction chromatography, affinity
chromatography
or ionic exchanged chromatography. It should be noted that, on the basis of
the data

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
4
reported in the literature, the global yields of purification of trypsin from
the crude extracts
are low and the obtained specific enzymatic activity is of a few Units/mg.
Moreover, the need to stabilize trypsins from autolysis during long
purification
process, working in the presence of Ca' and at low temperature, implies high
costs for the
scaling up to an industrial scale. More simple and effective processes of
purification are
therefore required.
Description of the invention
The invention provides a process for the purification of fish proteases from
fish
viscera, comprising:
a) Extraction of crude enzyme from fish viscera with a calcium chloride buffer
at
pH 7, filtration and ultrafiltration;
b) Extraction of the ultrafiltrate with an aqueous solution of CaCl2 having
conductivity 52 to 62 mS in a pH range of 7,8+8,2 followed by depth
filtration;
c) Purification by hydrophobic interaction chromatography of the filtrate
using as
stationary phases an agarose base matrix with straight chain alkyl ligands or
aryl ligands
and eluted by elution with buffers of low salt content and then with an
aqueous mixture of
water miscible organic solvents and a polyol;
d) Dialysis;
e) Optional freeze-drying.
The proteases obtained by the process of the invention have an average
specific
Trypsin activity of 240 U/mg 40 U/mg, Chymotrypsin activity of 4 2 U/mg,
Collagenase
activity of 0.04 0.02 U/mg and a Protease activity of 65 10 U/mg.
The process provides overall yields of solid fish proteases of 0.06-0.11% by
weight
of the cod viscera used as starting material.
Fish viscera are preferably cod viscera.
The extraction process of step a) is carried out at a temperature between 4
and 25 C.
The pH calcium chloride buffer has preferably a final concentration of 20 mM.
The ultrafiltration is preferably carried out using a membrane with a 1
kDalton cut

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
off whereas the agarose base matrix of the stationary phase used in step c)
presents aryl
ligands and a particle size distribution between 50 and 100 microns.
The chromatographic elution with buffers of low salt content in the step c) is
preferably done using a 1,5 M aqueous sodium acetate solution, the water-
miscible organic
5 solvent is isopropanol and the polyol is glycerol.
Step c) is preferably carried out at a temperature between 4 and 25 C.
Detailed description: definitions
Cellular lines tested for the detachment and dissociation of anchorage-
dependent cells from surfaces
PC12 cells (a cell line derived from a pheochromocytoma of the rat adrenal
medulla)
appear to possess specific receptors and responses to epidermal growth factor
(EGF)
(Huff and Guroff, 1979). The presence of such receptors could reflect a
hitherto
unidentified role of EGF during neuronal development or could, alternatively,
correlate
with the neoplastic nature of PC12 cells. PC12 cells provide a model for
studying chemical
disruption of processes associated with neuronal differentiation, synthesis,
storage and
release of neurotransmitters, function and regulation of ion channels and
interactions of
compounds with membrane bound receptors.
Induced pluripotent stem cells (iPSC) are a type of pluripotent stem cell that
can be
generated directly from adult cells. These cells can be differentiated into
the hepatic lineage
and provide an accurate model for liver diseases, drug screening and drug
toxicity testing
(Curr Stem Cell Res Ther. 2015;10(3):208-15).
Neuronal progenitor cells (NPC) are multipotent stem cells with the capability
to
differentiate into neurons and glial cells (oligodendrocytes and astrocytes).
Therefore,
successful in vitro neural progenitor cell expansion offers significant
therapeutic potential
for cell therapy applications.
Human bone osteosarcoma epithelial cells (U205) could satisfy the need for an
in
vivo metastatic model for osteosarcoma.

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
6
Enzymatic tests used
Trypsin activity. Enzymatic activity analyzed according to the method
described in
the USP 41 monograph.
Chymotrypsin activity. Enzymatic activity analyzed according to the method
described in the USP 41 monograph.
Collagenase type I activity. Enzymatic activity analyzed according to
protocols
described in the literature (Mandl, I.J. Clin. Invest. 32, 1323. 1953. Moore,
S. et al.,
J. Biol. Chem. 176, 367. 1948).
Protease activity. Enzymatic activity analyzed according to the method
described in
the USP 41 monograph.
The consistency of the claimed process was confirmed using different batches
of
cod viscera (caught at different times of the year) as starting material: the
obtained fish
proteases proved to have limited variability from batch to batch; this
variability does not
exceed the range of 15% with respect to the obtained specific enzymatic
activities.
The purified fish proteases prepared according to the process of the invention
present a peculiar enzymatic profile: in fact, while commercially available
marine trypsins
(such as marine proteases identified by the CAS registry number 534583-22-7)
show
trypsin activity around 26-49% and collagenase type I activity around 47-67%
of the total
enzymatic activity, the fish proteases prepared according to the process of
the invention
show trypsin activity of about 89-66% of the total enzymatic activity, and a
collagenase
activity of only 0.011-0.015%.
Surprisingly, the fish proteases prepared according process of the invention
when
utilized in histology for cell detachment, are less harmful to cells than
other marine
proteases, leading to increased viability. In detail, when NPC and PC12 cell
lines are treated
with the fish proteases obtained according to the invention, the survival rate
and the number
of recovered cells is about 5-10% higher than other trypsins/proteases of
mammalian and
marine origin.

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
7
Detailed description: process
Frozen (-20 C) cod viscera were thawed at 20-25 C, then combined with 20 mM
calcium chloride dihydrate extraction buffer in a relative ratio of 1 kg of
fish viscera for
2 L calcium chloride buffer. The resulting mixture was adjusted to a final pH
7 by addition
.. of sodium hydroxide 50% w/v water solution of and stirred for 8-12 hours at
4 C.
Large viscera chunks were separated by filtration with a net (1 mm cut-off).
A filter aid was added to the obtained mixture, under stirring at 20-25 C,
which was
then filter pressed.
Suitable filter aids are diatomaceous earth, perlite, cellulose added in a
amounts
comprised between 3 and 7% by weight with respect to the volume of the
mixture.
Preferably diatomaceous earth is used in an amount of 5% w/v with respect to
the mixture.
The filtered extract was concentrated by ultrafiltration (1 kDa cut off) to
42% of the
initial volume and stored at 4 C if not immediately used in the next
purification process.
The concentrated fish extract was warmed to 20-25 C and calcium chloride
dihydrate was
added to reach a final concentration comprised between 1,0 and 1,8 w/v,
preferably 1,4%
w/v. Sodium acetate was added to reach a final concentration between 1,0 and
2,0 M,
preferably 1.5 M, and the pH adjusted in a range between 7,8 and 8,2,
preferably 8.0, using
5 M sodium hydroxide water solution.
The correct concentration of the salts is obtained, when the conductivity of
the
mixture is comprised in a range between 54 and 62 mS, preferably between 56
and 60 mS.
After stirring the mixture for one hour at 20-25 C, a filter aid was added and
the
obtained suspension filtered. Suitable filter aids are diatomaceous earth,
perlite, cellulose
added in an amount comprised between 1 and 4% by with weight respect to the
volume of
the mixture. Preferably diatomaceous earth is used in an amount of 2% w/v with
respect to
the mixture.
The obtained suspension is then filtered using a filter press equipped with
suitable
depth filters. The operative pressure used for this filtration is comprised
between 50 and
70 psi, preferably 60 psi, and the suitable depth filters employed should have
a cut off

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
8
comprised between 6 and 9 microns. Preferred depth filters are cellulose
filters sheets or
rigid media filter contains porous metal, ceramic or plastic media. Preferably
XE-400 filter
sheets are used (Carlson filtration).
Then the obtained filtrate was purified by hydrophobic interaction
chromatography
(HIC): the ratio of the volume of the feed material to the volume of the used
stationary
phase is comprised between 4 and 8 volume/volume, preferably 6,7. The
preferred particle
size of the stationary phase is comprised between 50 and 100 microns,
preferably 75
microns. The stationary phases present an agarose base matrix with different
immobilized
ligands, such as straight chain alkyl ligands or aryl ligands. Preferred
ligands are aryl
.. ligands. The stationary phase prior use is washed with at least 3 bed
volumes of 0,1M
sodium hydroxide aqueous solution and then with 3 bed volumes of distilled
water. Then
the column was conditioned with 4 BV with a solution prepared using a sodium
acetate
aqueous solution at a concentration comprised between 1,0 and 2,0 M,
preferably 1,5 M, at
a pH value comprised between 7,8 and 8,2, preferably 8.0, obtained by addition
of a 5 M
sodium hydroxide solution. The solution and the eluates are fed at 1/10
ml/minute flow rate
with respect to the total volume of the stationary phase and at a pressure
comprised between
10 and 20 psi, preferably 15 psi. After the absorption, the bound solutes are
eluted by
stepwise or gradient elution with buffers with low salt content and then with
an aqueous
mixture of water miscible organic solvents and a polyol. Suitable water
miscible organic
solvents have a log P (hydrophobicity) comprised between -0.3 land +0.25, such
as
n-propanol, isopropanol and ethanol, preferably isopropanol. Suitable polyols
are glycerol,
ethylene glycol, ethylene glycol and sorbitol, preferably glycerol.
The elution is preferably effected under the following conditions: 2 bed
volumes of
1.5 M sodium acetate at pH 8, then elution with 3 bed volumes of a solution of
10% v/v
glycerol and 5% v/v isopropanol (diluted with distilled water). Eluates were
collected in 4
fractions of about 1 bed volume each. The eluted fractions with trypsin
activity were pooled
together, concentrated to 1/10 of the starting volume by ultrafiltration
(using an
ultrafiltration membrane with a cut off of lkDa). Then the concentrated
solution was diluted

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
9
under stirring to 1/2.2 with a 20 mM CaCl2 aqueous solution at pH 8, dialyzed
to restore
the original volume then freeze dried to afford a purified fish protease. 33-
60 g of purified
fish proteases with an average Trypsin enzymatic activity of 240 U/mg,
Chymotrypsin
activity of 5 U/mg and a collagenase activity of 0.04 U/mg were recovered from
52 Kg of
cod viscera. Optionally, the process of the invention can be stopped after the
dialysis step
(i.e. avoiding the final freeze drying step) to obtain fish proteases in
aqueous solution useful
for the preparation of enzymatic liquid formulations having a defined
enzymatic activity.
The consistency of the process was checked using different batches of cod
viscera
caught at different times of the year as starting material: the obtained fish
proteases were
confirmed to have a limited variability from batch to batch; this variability
does not exceed
the range of 15% with respect to the obtained enzymatic activities.
The invention is illustrated in more detail in the following examples.
EXAMPLE 1
Extraction of Crude Enzyme
52 kg of fish viscera was thawed overnight at room temperature, then combined
with 103 L of a 20 mM calcium chloride dihydrate extraction buffer in a
relative ratio of
1 kg of fish viscera: 2 L calcium chloride buffer. The resulting mixture
(about 150 L) was
adjusted to a final pH 7 value by addition of a sodium hydroxide water
solution 50% w/v
and stirred overnight at 4 C.
Large viscera chunks were separated by filtration with a net, leaving 130 L in
the
tank. 6.5 kg of diatomaceous earth (5% w/v) was added to the obtained mixture
under
stirring at room temperature, then filter pressed through 14 XE-400 filter
sheets
(7 cassettes). The filtered extract (100L) was concentrated to 42 L using a
lx1 ultrafiltration
spiral membrane (1kDa cut off). The membrane was cleaned prior to
concentrating with
100 L 0.1M sodium hydroxide water solution followed by reverse osmosis against
water.
2 L of concentrated fish extract was removed for freeze drying, and the rest
of the
extract was stored at 4 C until purification.

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
EXAMPLE 2
Hydrophobic Interaction Chromatography (HIC) purification
All purification steps were performed at 20-25 C. The concentrated fish
extract was
warmed to 20-25 C, and 58.82 g calcium chloride dihydrate was added. 4.93 kg
of sodium
5 acetate was added to obtain a 1.5 M concentration and the pH was adjusted
to 8 using 5 M
sodium hydroxide water solution.
The conductivity was checked to ensure that the correct concentration had been
reached (adjusted to 56-60 mS; was 57.4 mS). After stirring for one hour, 0.8
kg of
diatomaceous earth was added (2% w/v) and the obtained suspension was
clarified by filter
10 pressing through 4 XE-400 filter sheets (1 cassette). 40L of feed
material was obtained.
6 L of Capto-phenyl high sub column resin was conditioned with 20L of 0.1M
sodium hydroxide aqueous solution followed by 20 L reverse osmosis water.
Column pressure was maintained at 15 psi and a flow rate of 417 mL/minute. 40
L
of 1.5 M sodium acetate at pH 8 was used to equilibrate the column. The
eluates were also
checked for conductivity (expected value 62 mS).
Primed feed was added to the column, washed with 15 L of equilibration buffer,
then eluted with 20 L of a solution of 10% v/v glycerol and 5% v/v isopropanol
(diluted
with reverse osmosis water). Eluate was collected in 4 fractions, 5 L each,
and the fractions
with trypsin activity were pooled (15 L collected).
EXAMPLE 3
Eluate Concentration, Dialysis, Freeze Drying
Concentrations and diafiltrations were performed using a cross tangential
ultrafiltration unit with a lkDa membrane (Pall Filtron, USA). The selected
eluates were
concentrated to a final volume of 1.7 L. This solution was added with 1 L of
20 mM CaCl2
.. water solution at pH 8 under stirring.
The resulting solution had 4.3% solids. Additional 1 L of CaCl2 solution was
added
and the resulting solution showed 4.5% solids. The volume was reduced to 1.75
L by
dialysis, then the concentrated and diafiltered eluate was freeze dried to
afford 33g of

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
11
powder. The specific enzymatic activity of this powder was: Trypsin 240 U/mg,
Chymotrypsin 5 U/mg and Collagenase 0.04 U/mg. The isolated enzyme exhibited
several
bands on SDS-PAGE: the main one, indicated with an arrow in Figure 1, with an
estimated
molecular weight of 25,000.
Optionally the production process of fish proteases can be stopped after the
dialysis
step (i.e. avoiding the final freeze-drying step) to obtain fish proteases in
aqueous solution
at the desired concentration.
These solutions can be used for the preparation of final enzymatic
formulations in
phosphate-buffered saline solutions (PBS solutions) containing potassium
chloride,
potassium dihydrogen phosphate, sodium chloride, disodium monohydrogen
phosphate,
tetrasodium ethylenediaminetetraacetate and phenol red at a pH value comprise
between
7,2 and 7,6.
These enzymatic formulations may contain 0,1-0,3 g/L of potassium chloride and
potassium dihydrogen phosphate, 7-9 g/L of NaCl, 1,0-1,3 g/L of disodium
monohydrogen
phosphate, 2.4 mg/L of phenol red and sodium ethylenediaminetetraacetate at a
final
concentration ranging between 0,3 and 0,6 mM and include the Dulbecco's
phosphate-buffered saline solution (Dulbecco, R et al. J. Exp. Med., 99, 167-
182 (1954)).
EXAMPLE 4
Analytical characteristics of fish trypsin purified according to the invention
The characteristics of the fish trypsin isolated according to the invention
are
reported in the following Tables and in Figures.
Optimum temperature range for enzymatic activity: Table 1 and Figure 2 show
the
enzymatic activity of the prepared fish protease in the temperature range
comprised
between 5 and 70 C. Tested the main trypsin activity.

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
12
Table 1
Temp. (deg. C) Trypsin Activity (U/mg)
40
56
81
115
225
390
559
73
33
Optimum pH range for enzymatic activity: Table 2 and Figure 3 show the
enzymatic
activity of the prepared fish trypsin in the pH range comprised between 3 and
12. The main
5 trypsin activity has been tested.
Table 2
pH Trypsin Activity (U/mg)
3 0
4 3
5 15
6 83
7 147
8 173
9 160
10 0
11 1
12 2
Stability data for the enzymatic activity over time at different pH values:
Table 3
and Figure 4 show the enzymatic activity of the prepared fish trypsin in the
pH range of
3-10 in 3 hours at the temperature of 5 C. The same data of the Table 3 are
presented in
10 graphic form as relative enzymatic activity (100% of enzymatic activity
at time zero;
Figure 4). The main trypsin activity has been tested.
Table 3
trypsin activity (U/mg)
time (minutes) pH 3 pH 4 pH 5 pH 6 pH 7 pH 8 pH 9 pH 10
0 168 205 205 169 136 161 161 168
30 13 171 128 156 140 155 155 133
60 13 157 107 157 157 151 147 128
90 20 157 100 153 144 155 145 116
120 14 148 96 148 137 151 135 107
150 17 171 95 147 135 149 143 110
180 19 165 93 141 167 151 140 110

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
13
Cell culture: biological "in vivo" tests
Comparative in vitro biological tests in PC12 cells, Human Glioma and Human
Astrocyte were carried out using fish proteases prepared according to the
process of the
invention, compound with registry number 534583-22-7 and mammalian trypsin
having
approximately 3000 U/ml trypsin activity 0.25w/v% Trypsin-lmM EDTA/4Na
Solution
with Phenol Red (Wako, Japan 209-16941). Fish proteases prepared according to
the
invention recovered more PC12 cells than trypsin and the compound with
registry number
534583-22-7 (Table 4). Figure 5 shows the optical microscope observation of
PC12 cell
before and after treatment with Fish proteases prepared according to the
claimed process,
Accutaseg and mammalian trypsin.
Table 4. Survival rate (%) of PC12 cells after treatment with treatment with
Fish
proteases prepared according to the claimed process, compound with registry
number
534583-22-7 and Mammalian Trypsin.
PC12 cells
Enzyme Number of Ratio to
Survival rate
recovered cells Trypsin ['Yi]
[x10-5 cells/well]
Fish proteases 1.325 1.1 98.8
Compound with registry number 0.783 0.64 93.3
534583-22-7
Mammalian Trypsin 1.22 1 97.3
The survival rate obtained with fish proteases prepared according to the
claimed
process is comparable to that obtainable with the compound with CAS registry
number
534583-22-7 and to trypsin, depending on cell type; the best results with
these fish
proteases were obtained on PC12 cells (Table 5).
Table 5
Survival rate [%]
PC12 cells Human Glioma Human Astrocytes
Fish proteases 98.8 78.0 90.0
Accutase (ID 93.3 83.4 91.3
Mammalian Trypsin 97.3 98.1 97.0

CA 03139871 2021-11-10
WO 2020/229145 PCT/EP2020/061588
14
Further comparatives studies were carried out using the following cell lines:
iPSC
(induced pluripotent stem cells), NPC (neuronal progenitor cells) and U2OS
(human bone
osteosarcoma epithelial cells) in order to compare fish proteases obtained by
process of the
invention in comparison with mammalian trypsin having approximately 500-600
U/ml
.. trypsin activity (Tryp sin 0.05% / EDTA 0.53mM 10X IN HB S S lx, STERILE
(Wi sent
Bioproducts, Quebec, Canada) and with the compound with CAS registry number
534583-22-7, with particular attention to the characteristics of cell
attachment and viability
and the final cell morphology.
For this purpose, 5,000 cells/well in 12 well plate were cultured for 5 days,
starting
the experiment when the it reached 70% confluency; then the medium was
aspirated, rinsed
with PBS and 0.5 mL of dissociation reagent was added and incubated at 37 C
for 3 minutes
until dissociation (dissociation was monitored under the microscope until the
optimal time
was determined).
Table 6. Optimized incubation time of different enzymes for efficient
dissociation
on different cell lines
Cell lines Incubation time Incubation time Incubation time with
with with compound registry number
Fish proteases Trypsin 534583-22-7
iPSC 3 minutes 3 minutes 3 minutes
NPC 3 minutes 3 minutes 3 minutes
U205 14 minutes 3 minutes 3 minutes
DMEM (Dulbecco's Modified Eagle Medium) was added to stop the enzyme
reaction, then the cells were recovered by centrifugation at 1200 rpm for 3
min. The cells
were re-suspended the in-culture medium; the cells number was determined by
using lunar
automated cell counter (Table 7). Treatment with fish proteases of the
invention on iPSCs
and NPCs did not affect cell attachment and viability as observed with
trypsin.

CA 03139871 2021-11-10
WO 2020/229145
PCT/EP2020/061588
Table 7. Cell numbers and viability of different cell lines after the
enzymatic
treatments
Cell lines test Fish Mammalian Compound registry
proteases Trypsin number 534583-22-7
iPSC Cell number 0.5 x10' 1.1 x10' 2.95 x10'
Viability 89.63% 81.4% 92.06%
NPC Cell number 0.52x105 0.49x105 0.39x105
Viability 89.9% 86.9% 58.1%
U2OS Cell number 3.52x105 2.1x105 4.55x105
Viability 95.1% 100% 96.8%
The cells were re-plated onto 12 well containing the medium and observed by
5 optical microscopy after one week (Figure 6). On the basis of this
observations we
confirmed that the cells treated with fish proteases of the invention did not
change
morphology and appeared healthy.
The purified fish proteases prepared according to the process of the invention
present a peculiar enzymatic profile characterized by a trypsin activity of
about 60-80% of
10 the total enzymatic activity, collagenase activity being substantially
negligible (Table 8).
Table 8. % of enzymatic activities of fish proteases obtained according to the
process of the invention versus other commercially available proteases.
Fish proteases solution
Compound with registry Accutase TM XL
after diafiltration and
number 534583-22-7 (% of AccuMax TM (% of powder (% of
freeze drying (% of
enzymatic activity) enzymatic activity) enzymatic activity)
enzymatic activity)
Trypsin activity 29 49 26 78,0
Chymotrypsin activity 0 0 0 1,6
Collagenase type I activity 59 47 67 0,01
Protease activity 12 5 7 21,0

Representative Drawing

Sorry, the representative drawing for patent document number 3139871 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Letter Sent 2024-04-23
Request for Examination Requirements Determined Compliant 2024-04-22
Request for Examination Received 2024-04-22
All Requirements for Examination Determined Compliant 2024-04-22
Inactive: Cover page published 2022-01-11
Letter sent 2021-11-30
Inactive: IPC assigned 2021-11-29
Priority Claim Requirements Determined Compliant 2021-11-29
Request for Priority Received 2021-11-29
Application Received - PCT 2021-11-29
Inactive: First IPC assigned 2021-11-29
Inactive: IPC assigned 2021-11-29
Inactive: IPC assigned 2021-11-29
Inactive: IPC assigned 2021-11-29
National Entry Requirements Determined Compliant 2021-11-10
Application Published (Open to Public Inspection) 2020-11-19

Abandonment History

There is no abandonment history.

Maintenance Fee

The last payment was received on 2024-03-26

Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following

  • the reinstatement fee;
  • the late payment fee; or
  • additional fee to reverse deemed expiry.

Patent fees are adjusted on the 1st of January every year. The amounts above are the current amounts if received by December 31 of the current year.
Please refer to the CIPO Patent Fees web page to see all current fee amounts.

Fee History

Fee Type Anniversary Year Due Date Paid Date
Basic national fee - standard 2021-11-10 2021-11-10
MF (application, 2nd anniv.) - standard 02 2022-04-27 2022-03-31
MF (application, 3rd anniv.) - standard 03 2023-04-27 2023-03-28
MF (application, 4th anniv.) - standard 04 2024-04-29 2024-03-26
Request for examination - standard 2024-04-29 2024-04-22
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
BIOSEUTICA B.V.
Past Owners on Record
ALEX NOBAR YOUSIF
JAY SIDDHARTH
PRIYANKA DUTTA PASSECKER
VALERIO MARIA FERRARI
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Drawings 2021-11-09 3 2,027
Description 2021-11-09 15 663
Claims 2021-11-09 2 69
Abstract 2021-11-09 1 51
Maintenance fee payment 2024-03-25 2 61
Request for examination 2024-04-21 6 184
Courtesy - Acknowledgement of Request for Examination 2024-04-22 1 436
Courtesy - Letter Acknowledging PCT National Phase Entry 2021-11-29 1 595
Patent cooperation treaty (PCT) 2021-11-09 1 38
International search report 2021-11-09 3 124
National entry request 2021-11-09 7 242